Unexplored areas and new findings in lipid emulsion serving as a potential drug carrier for lipophilic drugs: A review

Trends in Medical Research

Volumn 7, Issue 1, 2012, Pages 1-24

  Angare, Dixha ^a   Giri, Tapan ^a   Tripathi, Dulal Krishna ^a   Alexander, Amit ^a   Ajazuddin, ^a  

^a RUNGTA COLLEGE OF PHARMACEUTICAL SCIENCES AND RESEARCH   (India)

Author keywords

Biotransformation; Emulsifier; Lipid emulsion introduction; Oil; Solubility; Stability

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIOXIDANT; APOMORPHINE; AZITHROMYCIN; BUFFER; CHELATING AGENT; CYCLOSPORIN; DEXAMETHASONE; DIAZEPAM; DIFLUPREDNATE; DRUG; EMULSIFYING AGENT; ETOMIDATE; EXCIPIENT; FLURBIPROFEN AXETIL; INTRALIPID; LATANOPROST; LIMETHASON; LIPID EMULSION; LIPOPHILIC AGENT; LIPOPROSTAGLANDIN E1; MORPHINE; MULTIVITAMIN; OIL; PHYSOSTIGMINE SALICYLATE; PIROXICAM; PRESERVATIVE; PROPOFOL; ROPION; TOCOPHEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITALIPID;

ANALGESIC ACTIVITY; AQUEOUS SOLUTION; ARTICLE; CHEMICAL COMPOSITION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG EFFICACY; DRUG FORMULATION; DRUG MARKETING; DRUG RELEASE; DRUG RESEARCH; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; DRUG TOLERABILITY; DRUG TRANSFORMATION; ENCAPSULATION; EXCIPIENT COMPATIBILITY; FLOW KINETICS; HOMOGENATE; HUMAN; HYDROPHILICITY; LIGHT SCATTERING; LIPOPHILICITY; MALNUTRITION; PARENTERAL NUTRITION; PARTICLE SIZE; PHAGOCYTOSIS; PHYSICAL CHEMISTRY; RISK BENEFIT ANALYSIS; SURFACE PROPERTY; TEMPERATURE SENSITIVITY; ZETA POTENTIAL;

EID: 84858172812     PISSN: 18193587     EISSN: 21516065     Source Type: Journal    
DOI: 10.3923/tmr.2012.1.24     Document Type: Article

References (146)

1. Abdurahman, H.N. and R.M. Yunus, 2009. Coalescence of water droplets in water-in-crude oilemulsions. Int. J. Chem. Technol., 1: 19-25.
2. Abdurahman, H.N., M.A.A. Hassan and R.M. Yunus, 2007. Characterization and demulsificationof water-in-crude oil emulsions. J. Applied Sci., 7: 1437-1441.
3. Abdurahman, H.N., F.S. Mohammed, R.M. Yunus and A. Annan, 2009. Demulsification of virgincoconut oil by centrifugation method: A feasibility study. Int. J. Chem. Technol., 1: 59-64.
4. Allen, C, N.D. Santos, R. Gallagher, G.N.C. Chiu and Y. Shu et al, 2002. Controlling the physicalbehavior and biological performance of liposome formulations through use of surface graftedpolyethylene glycol). Biosci. Rep., 22: 225-250.
5. Anisa, A.N.I., A.H. Nour and A.H. Nour, 2011. Destabilization of heavy and light crude oilemulsions via microwave heating technology: An optimization study. J. Applied Sci.,113: 2898-2906.
6. Anne, M.F., 2008. Using emulsifier wax. http://www.teachsoap.com/emulsifywax.html
7. Atkins, P.J. and P. Loretta, 2005. Chemical principles: The quest for insight. Int. J. Pharmaceut., 3: 20-22.
8. Awasthi, V.D., D. Garcia, B.A. Goins and W.T. Phillips, 2003. Circulation and biodistribution profiles of long-circulating PEG-liposomes of various sizes in rabbits. Int. J. Pharmaceut., 253: 121-132.
9. Balamuralidhara, V., T.M. Pramodkumar, N. Srujana, M.P. Venkatesh, N.V. Gupta, K.L. Krishna and H.V. Gangadharappa, 2011. pH sensitive drug delivery systems: A review. Am. J. Drug Discovery Dev., 1: 24-48.
10. Benita, S., D. Friedman and M. Weinstock, 1986. Pharmacological evaluation of an injectableprolonged release emulsion of physostigmine in rabbits. J. Pharm. Pharmacol., 38: 653-658.
11. Blume, G. and G. Cevc, 1993. Molecular mechanism of the lipid vesicle longevity in vivo.Biochim. Biophys. Acta, 1146: 157-168.
12. Boberg, J. and I. Hakansson, 1964. Physical and biological changes in an artificial fat emulsionduring storage. J. Pharm. Pharmacol., 16: 641-646.
13. Boode, K., C. Bisperink and P. Walstra, 1991. Destabilization of O/W emulsions containing fatcrystals by temperature cycling. Colloids Surf., 61: 55-74.
14. Boode, K., P. Walstra and A.E.A. Degrootmostert, 1993. Partial coalescence in oil-in-wateremulsions: Influence of the properties of the fat. Colloids Surf. A: Physicochemical Eng. Aspects,81: 139-151.
15. Carlson, L.A. and D. Hallberg, 1963. Studies on elimination of exogenous lipids from the bloodstream: The kinetics of the elimination of a fat emulsion and of chylomicrons in the dog aftera single injection. Acta Physiol. Scand., 59: 52-61.
16. Carpentier, Y.A., C. Simoens, V. Siderova, I. El Nakadi, V. Vanweyengerg, D. Eggerickx and R.J. Deckelbaum, 1997. Recent developments in lipid emulsions: Relevance intensive care. Nutrition, 13: 74-77.
17. Chanana, G.D. and B.B. Sheth, 1993. Particle size reduction of emulsions by formulation design. I: Effect of polyhydroxy alcohols. J. Parenter. Sci. Technol., 47: 130-134.
18. Chansri, N., S. Kawakami, F. Yamashita and M. Hashida, 2006. Inhibition of liver metastasis by all-trans retinoic acid incorporated into O/W emulsions in mice. Int. J. Pharm., 321: 42-49.
19. Chinsriwongkul, A., P. Opanasopit, T. Ngawhirunpat, N. Chareansriwilaiwat, W. Sila-On and U. Ruktanonchai, 2007. Physicochemical properties of lipid emulsions formulated with high-load All-^rans-retinoic acid. PDA J. Pharm. Sci. Technol., 61: 461-471.
20. Choi, W.J, J.K Kim, S.H. Choi, J.S. Park, W.S. Ahn and C.K. Kim, 2004. Low toxicity of cationic lipid-based emulsion for gene transfer. Biomaterials, 25: 5893-5903.
21. Cohen, T, H. Sauvageon-Martre, D. Brossard, F.D. Hermies, C. Bardin, F. Chast and J.C. Chaumeil, 1996. Amphotericin B eye drops as a lipidic emulsion. Int. J. Pharm, 137: 249-254.
22. Davis, M, C.J. Simmons, B. Dordoni and R. Williams, 1974. Urinary D-glucaric acid excretion and plasma antipyrine kinetics during enzyme induction. Br. J. Clin. Pharmacol, 1: 253-257.
23. Davis, S.S. and M. Galloway, 1986. Studies on fat emulsions in combined nutrition solutions. J. Clin. Hosp. Pharm, 11: 33-45.
24. Davis, S.S, 1974. Pharmaceutical aspects of intravenous fat emulsions. J. Hosp. Pharm, 32: 149-171.
25. Davis, S.S, C. Washington, P. West, L. Ilium, G. Liversidge, L. Sternson and R. Kirsh, 1987. Lipid emulsions as drug delivery systems. Ann. NY. Acad. Sci, 507: 75-88.
26. Day, L., M. Xu, P. Hoobin, I. Burgar and M.A. Augustin, 2007. Characterisation of fish oilemulsions stabilised by sodium caseinate. Food Chem., 105: 469-479.
27. Deharo, E., M. Krugliak, D. Baccam and H. Ginsburg, 1995. Antimalarial properties of soy-beanfat emulsions. Int. J. Parasitol., 25: 1457-1462.
28. Dickinson, E. and D.J. McClements, 1995. Fat Crystallization in Oil-in-Water Emulsions. BlackieAcademic and Professional, New York, USA., pp: 211-246.
29. Driver, I., J.W. Feather, P.R. King and J.B. Dawson, 1989. The optical properties of aqueoussuspensions of Intralipid, a fat emulsion. Phys. Med. Biol., 34: 1927-1930.
30. Dudrick, S.J., 2003. Early developments and clinical applications of total parenteral nutrition. JPEN J. Parenter. Nutr, 27: 291-299.
31. Dunn, S.E., A. Brindley, S.S. Davis, M.C. Davies and L. Ilium, 1994. Polystyrene-poly (ethyleneglycol) (PS-PEG2000) particles as model systems for site specific drug delivery. 2. The effect ofPEG surface density on the in vitro cell interaction and in vivo biodistribution. Pharm. Res.,11: 1016-1022.
32. Edgren, B. and A. Wretlind, 1963. The theoretical background of the intravenous nutrition withfat emulsions. Nutr. Dieta. Eur. Rev. Nutr. Diet, 13: 364-386.
33. Engels, P.T. and J.S. Davidow, 2010. Intravenous fat emulsion to reverse haemodynamicinstability from intentional amitriptyline overdose. Resuscitation, 81: 1037-1039.
34. Fang, J.Y., Y.L. Leu, C.C. Chang, C.H. Lin and Y.H. Tsai, 2004. Lipid nano/submicron emulsionsas vehicles for topical flurbiprofen. Drug Delivery, 11: 97-105.
35. Floyd, A.G., 1999. Top ten considerations in the development of parenteral emulsions. Pharm. Sci.Technol. Today, 2: 134-143.
36. Foxall, G., R. McCahon, J. Lamb, J.G. Hardman and N.M. Bedforth, 2007. Levobupivacaine-induced seizures and cardiovascular collapse treated with Intralipid. Anaesthesia, 62: 516-518.
37. Gao, K., J. Sun, K. Liu, X. Liu and Z. He, 2008. Preparation and characterization of a submicronlipid emulsion of docetaxel: Submicron lipid emulsion of docetaxel. Drug Develop. Ind. Pharm.,34: 1227-1237.
38. Gonyon, T., P. Patel, H. Owen, A.J. Dunham and P.W. Carter, 2007. Physicochemical stability oflipid injectable emulsions: Correlating changes in large globule distributions with phaseseparation behavior. Int. J. Pharm., 343: 208-219.
39. Granot, E., B. Schwiegelshohn, I. Tabas, M. Gorecki, T. Vogel, Y.A. Carpentier and R.J. Deckelbaum 1994. Effects of particle size on cell uptake of model triglyceride-rich particleswith and without apoprotein E. Biochemistry, 33: 15190-15197.
40. Granot, E., R.J. Deckelbaum, S. Eisenberg, Y. Oschry and G. Bengtsson-Olivecrona, 1985. Coremodification of human low-density lipoprotein by artificial triacylglycerol emulsion. Biochim.Biophys. Acta, 833: 308-315.
41. Hallberg, D., O. Schuberth and A. Wretlind, 1966. Experimental and clinical studies with fatemulsion for intravenous nutrition. Nutr. Dieta. Eur. Rev. Nutr. Diet., 8: 245-281.
42. Hanna, G.K., M.C. Ojeda and T.A. Sklenar, 1992. Application of computer-based experimentaldesign to optimization of processing conditions for perfluorocarbon emulsion. Biomater. Artif.Cells Immobilization Biotechnol., 20: 849-852.
43. Harris, D.C., 2003. Quantitative Chemical Analysis. 6th Edn., W.H. Freeman and Co., New York,USA, ISBN-13: 9780716744641, Pages: 928.
44. Hrrata, M.H, H.C.F. Ohverra, E.C.R. Qumtao, T.G Redgrave and R.C. Maranhao, 1987. The effects of Triton WR-1339, protamine sulfate and heparin on the plasma removal of emulsion models of chylomicrons and remnants in rats. Biochim. Biophys. Acta (BBA)-Lipids Lipid Metab, 917: 344-346.
45. Hung, C.F, T.L. Hwang, C.C. Chang and J.Y. Fang, 2005. Physicochemical characterization and gene transfection efficiency of lipid emulsions with various co-emulsifiers. Int. J. Pharm, 289: 197-208.
46. Hutlin, M, C. Carneheim, K. Rosenqvist and T. Olivecrona, 1995. Intravenous lipid emulsions: Removal mechanisms as compared to chylomicrons. J. Lipid Res, 36: 2174-2184.
47. Igarashi, R, M. Takenaga and T. Matsuda, 1996. Distribution of the lipid microsphere preparations. Adv. Drug Deliv. Rev, 20: 147-154.
48. Issaka, S.A, A.H. Nour, R.M. Yunus and A.H. Nour, 2010. Decolorization and characterization of petroleum emulsions. J. Applied Sciences, 10: 215-220.
49. Ivancev, K, A. Lunderqmst, R. McCuskey, P. McCuskey and A. Wretlmd, 1989. Effect of intravenously injected iodinated lipid emulsion on the liver. An experimental study correlating computed tomography findings with in vivo microscopy and electron microscopy findings. Acta Radiol, 30: 291-298.
50. Jain, R.K, 1989. Delivery of novel therapeutic agents in tumors: Physiological barriers andstrategies. J. Natl. Cancer Inst, 81: 570-576.
51. Jang, J.H, C.K. Kim, H.G. Choi and J.H. Sung, 2009. Preparation and evaluation of 2-(allylthio)pyrazine-loaded lipid emulsion with enhanced stability and liver targeting. Drug Dev. Ind.Pharm, 35: 363-368.
52. Joly, V, C. Geoffray, J. Reynes, C. Goujard and D. Mechali et al., 1996. Amphotericin B in a lipidemulsion for the treatment of cryptococcal meningitis in AIDS patients. J. Antimicrob.Chemother, 38: 117-126.
53. Jonkman-De Vries, J.D, K.P. Flora, A. Bult and J.H. Beijnen, 1996. Pharmaceutical developmentof (Investigational) anticancer agents for parenteral use: A review. Drug Develop. Ind. Pharm,22: 475-494.
54. Jumaa, M. and B.W. Muller, 1998a. The effect of oil components and homogenization conditions on the physicochemical properties and stability of parenteral fat emulsions. Int. J. Pharm, 163: 81-89.
55. Jumaa, M. and B.W. Muller, 1998b. The stabilization of parenteral fat emulsion using non-ionicABA copolymer surfactant. Int. J. Pharm, 174: 29-37.
56. Jumaa, M, P. Kleinebudde and B.W. Muller, 1998. Mixture experiments with the oil phase ofparenteral emulsions. Eur. J. Pharm. Biopharm, 46: 161-167.
57. Jumaa, M, P. Kleinebudde and B.W. Muller, 1999. Physicochemical properties and hemolytic effectof different lipid emulsion formulations using a mixture of emulsifiers. Pharm. Acta Helvetiae,73: 293-301.
58. Jumaa, M. and B.W. Muller, 2001. Development of a novel parenteral formulation for tetrazepamusing a lipid emulsion. Drug Develop. Ind. Pharm, 27: 1115-1121.
59. Kandadi, P, M.A. Syed, S. Goparaboina and K. Veerabrahma, 2011. Brain specific delivery ofpegylated indinavir submicron lipid emulsions. Eur. J. Pharm. Sci, 42: 423-432.
60. Kellner, A, J.W. Correll and A.T. Ladd, 1951. Sustained hyperlipemia induced in rabbits by meansof intravenously injected surface-active agents. J. Exp. Med, 93: 373-383.
61. Khairi, M.S.F, 2007. Analysis of preservatives in pharmaceutical products. http://www.pharmainfo.net/reviews/analysis-preservatives-pharmaceutical-products
62. Klang, S.H, A. Baszkin and S. Benita, 1996. The stability of piroxicam incorporated in a positively-charged submicron emulsion for ocular administration. Int. J. Pharm, 132: 33-44.
63. Klinkesorn, U, P. Sophanodora, P. Chinachoti and D.J. McClements, 2004. Stability and rheology of corn-oil-in-water emulsions containing maltodextrin. Food Res. Int., 37: 851-859.
64. Koletzko, B, 2002. Parenteral lipid infusion in infancy: Physiology basis and clinical relevance. Clin. Nutr, 21: 53-65.
65. Kurihara, A, Y. Shibayama, A. Mizota, A. Yasuno and M. Ikeda et al., 1996. Lipid emulsions of palmitoylrhizoxin: effects of composition on lipolysis and biodistribution. Biopharm. Drug Dispos, 17: 331-342.
66. Kwon, S.M, H.Y. Nam, T. Nam, K. Park and S. Lee et al., 2008. In vivo time-dependent geneexpression of cationic lipid-based emulsion as a stable and biocompatible non-viral gene carrier.J. Controlled Release, 128: 89-97.
67. Lee, V.H. and J.R. Robinson, 1986. Topical ocular drug delivery: Recent developments and futurechallenges. J. Ocul. Pharmacol, 2: 67-108.
68. Lenzo, N.P, I. Martins, B.C. Mortimer and T.G. Redgrave, 1988. Effects of phospholipidcomposition on the metabolism of triacylglycerol, cholesteryl ester and phosphatidylcholine fromlipid emulsions injected intravenously in rats. Biochim. Biophys. Acta, 960: 111-118.
69. Levy, M.Y. and S. Benita, 1989. Design and characterization of a submicronized o/w emulsion ofdiazepam for parenteral use. Int. J. Pharm, 54: 103-112.
70. Litz, R.J, M. Popp, S.N. Stehr and T. Koch, 2006. Successful resuscitation of a patient withropivacaine-induced asystole after axillary plexus block using lipid infusion. Anaesthesia,61: 800-801.
71. Liu, F. and D. Liu, 1995. Long-circulating emulsions (oil-in-water) as carriers for lipophilic drugs. Pharm. Res, 12: 1060-1064.
72. Liu, K.S, K.C. Sung, S.A. Al-Suwayeh, M.C. Ku, C.C. Chu, J.J. Wang and J.Y. Fang, 2011.Enhancement of transdermal apomorphine delivery with a diester prodrug strategy. Eur. J.Pharm. Biopharm, 78: 422-431.
73. Liu, Y, X. Lin and X. Tang, 2009. Lipid emulsions as a potential delivery system for ocular use ofazithromycin. Drug Dev. Ind. Pharm, 35: 887-896.
74. Lundberg, B, 1991. Techniques for Complexing Pharmacological Agents to Lipoproteins and LipidMicroemulsions. In: Lipoproteins as Carriers of Pharmacological Agents, Shaw, J.M. (Ed.).Dekker, New York, pp: 97-141.
75. Lundberg, B, 1994. Preparation of drug-carrier emulsions stabilized with phosphatidylcholine-surfactant mixtures. J. Pharm. Sci, 83: 72-75.
76. Lundberg, B.B, B.C. Mortimer and T.G. Redgrave, 1996. Submicron lipid emulsions containingamphipathic polyethylene glycol for use as drug-carriers with prolonged circulation time. Int.J. Pharm, 134: 119-127.
77. MacLaren, R, B.A. Wachsman, D.K. Swift and D.A. Kuhl, 1997. Warfarin resistance associatedwith intravenous lipid administration: Discussion of propofol and review of the literature. Pharmacotherapy, 17: 1331-1337.
78. Maranhao, R.C, A.M. Tercyak and T.G. Redgrave, 1986. Effects of cholesterol content on themetabolism of protein-free emulsion models of lipoproteins. Biochim. Biophys. Acta,875: 247-255.
79. Mimi, N.T, C. Changb, Y.A. Carpentier and R.J. Deckelbauma, 2005. In vivo and in vitroproperties of an intravenous lipid emulsion containing only medium chain and fish oiltriglycerides. Clin. Nutr, 24: 492-501.
80. Mitra, R, I. Pezron, W.A. Chu and A.K. Mitra, 2000. Lipid emulsions as vehicles for enhancednasal delivery of insulin. Int. J. Pharm, 205: 127-134.
81. Morgan, T, G. Drew and D.K. Harry, 1920. Researches on residual affinity and co-ordination,Part II. Acetyl acetones of selenium and tellurium. J. Chem. Soc. Trans, 117: 1456-1464.
82. Muller, R, H. Auffret, T. Roudier, J. Vigneau and G.W. Simon et al., 1992. Evolution andadvection of solar mesogranulation. Nature, 356: 322-325.
83. Muller, R.H. and S. Heinemann, 1992. Fat emulsions for parenteral nutrition, Evaluation ofmicroscopic and laser light scattering methods for the determination of the physical stability. Clin. Nutr, 11: 223-236.
84. Nour, A.H, R.M. Yunus and A.H. Nour, 2010. Demulsification of water-in-oil emulsion bymicrowave heating technology. World Acad. Sci. Eng. Technol, 62: 1131-1138.
85. Othman, N, R. Djamal, N. Mili and S.N. Zailani, 2011. Removal of red 3BS dye from wastewaterusing emulsion liquid membrane process. J. Applied Sci, 11: 1406-1410.
86. Papahadjopoulos, D, T.M. Allen, A. Gabizon, E. Mayhew and K. Matthay et al., 1991. Stericallystabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. USA, 88: 11460-11464.
87. Pathak, V.Y, A. Rubinstein and S. Benita, 1990. Enhanced stability of physostigmine salicylatein submicron o/w emulsion. Int. J. Pharmaceutics, 65: 169-175.
88. Patlolla, R.R. and V. Vobalaboina, 2005. Pharmacokinetics and tissue distribution of etoposidedelivered in parenteral emulsion. J. Pharm. Sci, 94: 437-445.
89. Peterson, J, B.E. Bihain, G. Bengtsson-Olivecrona, R.I. Deckelbaum, Y.A. Carpentier and T. Olivecrona, 1990. Fatty acid control of lipoprotein lipase: A link between energy metabolismand lipid transport. Proc. Natl. Acad. Sci, 87: 909-913.
90. Picard, J. and T. Meek, 2006. Lipid emulsion to treat overdose of local anaesthetic: The gift of theglob. Anaesthesia, 61: 107-109.
91. Pontes-Arruda, A, 2009. Biological benefits of an oleic acid-rich lipid emulsion for parenteralnutrition. Clin. Nutr. Supplements, 4: 19-23.
92. Redgrave, T.G. and R.C. Maranhao, 1985. Pharmacodynamic evaluation of parenteral diclofenacsubmicron lipid emulsions. Biochim. Biophys. Acta, 835: 104-112.
93. Redgrave, T.G, V. Rakic, B.C. Mortimer and J.C. Mamo, 1992. Effects of sphingomyelin andphosphatidylcholine acyl chains on the clearance of triacylglycerol-rich lipoproteins fromplasma. Studies with lipid emulsions in rats. Biochim. Biophys. Acta, 1126: 65-72.
94. Reitmeier, R.E, V. Sivertz and H.V. Tartar, 1940. Some properties of monoethanolamine and itsaqueous solutions. J. Am. Chem. Soc, 62: 1943-1944.
95. Richelle, M, J. Bury, A. Kasry, R.J. Deckelbaum and Y.A. Carpentier, 1986. In vitro exchangesof lipids and apoproteins between HDL and exogenous fat. Clin. Nutr, 5: 55-55.
96. Riess, J.G, 1994. Novel fluorocarbon based injectable oxygen carrying formulation with long termroom temperature storage study. Adv. Exp. Med. Biol, 345: 227-234.
97. Rosenblatt, M.A, M. Abel, G.W. Fischer, C.J. Itzkovich and J.B. Eisenkraft, 2006. Successful useof a 20% lipid emulsion to resuscitate a patient after a presumed bupivacaine-related cardiacarrest. Anesthesiology, 105: 217-218.
98. Rubin, L.L, D.E. Hall, S. Porter, K. Barbu and C. Cannon et al., 1991. A cell culture model of thebloodbram barrier. J. Cell Biol, 115: 1725-1735.
99. Rubin, M, A. Moser, N. Vaserberg, F. Greig and Y. Levy et al, 2000. Structured triacylglycerolemulsion, containing both medium- and long-chain fatty acids, in long-term home parenteralnutrition: a double-blind randomized cross-over study. Nutrition, 16: 95-100.
100. Sakaeda, T. and K. Hirano, 1998. O/W lipid emulsions for parenteral drug delivery. 111.lipophilicity necessary for incorporation in oil particles even after intravenous injection. J. Drug Target, 6: 119-127.
101. Sakai, Y, S. Yasueda and A. Ohtori, 2005. Stability of latanoprost in an ophthalmic lipid emulsionusing polyvinyl alcohol. Int. J. Pharm, 305: 176-179.
102. Sane, S, M. Baba, C. Kusano, K. Shirao, T. Kamada and T. Aikou, 1999. Fat emulsionadministration in the early postoperative period in patients undergoing esophagectomy forcarcinoma depresses arachidonic acid metabolism in neutrophils. Nutrition, 15: 341-346.
103. Schneider, M.L, 1992. Lecithin - pharmaceutical applications expanded beyond liposomes. Cell.Mol. biol. lett, 10: 2005-2005.
104. Schuberth, O, 1961. Intravenous Infusion of Fat Emulsions, Phosphatides and EmulsifyingAgents. Stockholm: Acta chirurgica Scandinavica, Sweden, Pages: 21.
105. Seki, J, S. Sonoke, A. Saheki, H. Fukui, H. Sasaki and T. Mayumib, 2004. A nanometer lipidemulsion, lipid nano-sphere (LNS), as a parenteral drug carrier for passive drug targeting. Int. J. Pharm, 273: 75-83.
106. Semple, S.C, R. Leone, J. Wang, E.C. Leng and K.S. Klimuk et al., 2005. Optimization andcharacterization of a sphingomyelin/cholesterol liposome for-mulation of vinorelbine withpromising antitumor activity. J. Pharm. Sci, 94: 1024-1038.
107. Senior, J, C. Delgado, D. Fisher, C. Tilcock and G. Gregoriadis, 1991. Influence of surfacehydrophilicity of liposomes on their interaction with plasma protein and clear-ance from thecirculation: studies with poly (ethylene glycol) coated vesicles. Biochem. Biophys. Acta,1062: 77-82.
108. Shen, J, L. Gan, C. Zhu, X. Zhang and Y. Dong et al, 2001. Novel NSAIDs ophthalmicformulation: Flurbiprofen axetil emulsion with low irritancy and improved anti-inflammationeffect. Int. J. Pharm, 412: 115-122.
109. Shi, S, H. Chen, Y. Cui and X. Tang, 2009. Formulation, stability and degradation kinetics ofintravenous cinnarizine lipid emulsion. Int. J. Pharm, 373: 147-155.
110. Shinoda, K. and H. Saito, 1969. The stability of O/W type emulsions as functions of temperatureand the HLB of emulsifiers: The emulsification by PIT-method. J. Colloid Interface Sci,30: 258-263.
111. Simovic, S, H. Hui, Y. Song, A.K. Davey, T. Rades and OA. Prestidge, 2010. An oral deliverysystem for indomethicin engineered from cationic lipid emulsions and silica nanoparticles.J. Control. Release, 143: 367-373.
112. Sinko, P.J, 2006. Martin's Physical Pharmacy and Pharmaceutical Sciences. 5th Edn, LippincottWilliams and Wilkms, Philadelphia, USA, pp: 509-519.
113. Song, Y.K, D. Liu, K. Maruyama and T. Takizawa, 1996. Antibody mediated lung targeting oflong circulating emulsions. PDA J. Pharmaceut. Sci. Tech, 50: 372-377.
114. Spengler, R.F, J.B. Arrowsmith, D.J. Kilarski, C. Buchanan, L. Von Behren and D.R. Graham,1988. Severe soft-tissue injury following intravenous infusion of phenytoin. Patient and drugadministration risk factors. Arch. Int. Med, 148: 1329-1333.
115. Stevens, J, P. Minis and N. Coles, 2003. Lipid emulsions as drug delivery systems. Report,Technology and Services. http://www.touchbriefings.com/pdf/17/ACF9CFB.pdf
116. Studley, H.O, 1936. Percentage weight loss. A basic indicator of surgical risk in patients with chronic peptic ulcer. JAMA, 106: 458-466.
117. Su, M, M. Zhao, Y. Luo, X. Lin and L. Xu et al., 2011. Evaluation of the efficacy, toxicity and safety of vinorelbine incorporated in a lipid emulsion. Int. J. Pharm, 411: 188-196.
118. Sundar, S, L.B. Gupta, V.l Rastogi, G. Agrawal and H.W. Murray, 2000. Short-course, cost-effective treatment with Amphotericin B-fat emulsion visceral leishmaniasis. Ttrans. Royal Soc. Trop. Med. Hyg, 94: 200-204.
119. Sznitowska, M, S. Janicki, E.A. Dabrowska and M. Gajewska, 2002. Physicochemical screening of antimicrobial agents as potential preservatives for submicron emulsions. Eur. J. Pharm. Sci, 15: 489-495.
120. Takino, K, Y. Konishi, M. Takakura and M. Hashida, 1994. Long circulating emulsion carriersystems for highly lipophilic drugs. Biol. Pharm. Bull, 17: 121-125.
121. Tamilvanan, S, 2004. Oil-in-water lipid emulsions: Implications for parenteral and oculardelivering systems. Prog. Lipid Res, 43: 489-533.
122. Tashiro, T, H. Yamamori, N. Hayashi, T. Sugiura and K. Takagi et al., 1998. Effects of a newlydeveloped fat emulsion containing eicosapentaenoic acid and docosahexaenoic acid on fatty acidprofiles in rats. Nutrition, 14: 372-375.
123. ®) in chronicintestinal failure. Clin. Nutr, 23: 697-703.
124. Tokle, T. and D.J. McClements, 2011. Physicochemical properties of lactoferrin stabilized oil-in-water emulsions: Effects of pH, salt and heating. Food Hydrocolloids, 25: 976-982.
125. Tsuzuki, W, A. Ue, A. Nagao, M. Endo and M. Abe, 2004. Inhibitory effect oflysophosphatidylcholine on pancreatic lipase-mediated hydrolysis in lipid emulsion. Biochim.Biophys. Acta Mol. Cell Biol. Lipids, 1684: 1-7.
126. Ueda, K, M. Ishida, T. Inoue, M. Fujimoto, Y. Kawahara, T. Sakaedah and S. Iwakawa, 2001.Effect of injection volume on the pharmacokinetics of oil parenteral and ocular deliveringsystems. Prog. Lipid Res, 43: 489-533.
127. Van Boekel, M.A.J.S. and P. Walstra, 1981. Stability of oil-in-water emulsions with crystals in thedisperse phase. Colloids Surface, 3: 109-118.
128. Varshika, E, K. Prabhakar and V. Kishan, 2009. Preparation, characterization and in vivopharmacodynamic evaluation of parenteral diclofenac submicron lipid emulsions. PDA J.Pharm. Sci. Technol, 63: 380-389.
129. Venkateswarlu, V. and P.R. Reddy, 2001. Lipid microspheres as drug delivery systems. Indian J.Pharm. Sci, 63: 450-458.
130. Vinnars, E, L. Hammerqvist and A. Wretlinds, 2004. The history of nutrition. Clin. Nutr,23: 955-962.
131. Vyas, S.P. and R.K. Khar, 2002. Targated and Controlled Drug Delivery: Novel Carrier System. 1st Edn, CBS Publishers and Distributors, New Delhi.
132. Wang, J.J, K.C. Sung, O.Y.P. Hu, C.H. Yeh and JY. Fang, 2006. Submicron lipid emulsion as adrug delivery system for nalbuphine and its prodrugs. J. Controlled Release, 115: 140-149.
133. Washington, C. and S.S. Davis, 1988. The production of parenteral feeding emulsions byMicrofluidizer. Int. J. Pharm, 44: 169-176.
134. Washington, C, 1990. The stability of intravenous fat emulsions in total parenteral nutritionmixtures. Int. J. Pharm, 66: 1-21.
135. Washington, C, A. Chawla, N. Christy and S.S. Davis, 1989. The electrokinetic properties ofphospholipid-stabilized fat emulsions. Int. J. Pharm, 54: 191-197.
136. Webb, A.N, P. Hardy, M. Peterkm, O. Lee and H. Shalley et al, 2008. Tolerability and safety ofolive oil based lipid emulsion in critically ill neonates: A blinded randomized trial. Nutrition,24: 1057-1064.
137. Wei, C, J. Hua, C. Bin and K. Klassen, 2010. Impact of lipid emulsion containing fish oil onoutcomes of surgical patients: Systematic review of randomized controlled trials from Europeand Asia. Nutrition, 26: 474-481.
138. Weidmann, B, C. Lepique, A. Heider, A. Schmitz and N. Niederle, 1997. Hypersensitivity reactionsto parenteral lipid solution. Support Care Cancer, 5: 504-505.
139. Weinberg, G, R. Ripper, D.L. Feinstein and W. Hoffman, 2003. Lipid emulsion infusion rescuesdogs from bupivacaine-induced cardiac toxicity. Regional Anesthesia Pain Med, 28: 198-202.
140. Weingarten, C, N.S.S. Magalhaes, A. Baszkin, S. Benita and M. Seiller, 1991. Interaction of non-ionic ABA copolymer surfactant with phospholipid monolayers: Possible relevance to emulsionstabilization. Int. J. Pharm, 75: 171-179.
141. Wretlind, A, 1972. Complete intravenous nutrition. Theoretical and experimental background.Nutr. Metab, 14: 1-57.
142. Wretlind, A, 1981. Development of fat emulsions. J. Parenter Enteral Nutr, 57: 230-235.
143. Yamaguchi, M, S. Yasueda, A. Isowaki, M. Yamamoto, M. Kimura, K. Inada and A. Ohtori, 2005.Formulation of an ophthalmic lipid emulsion containing an anti-inflammatory steroidal drug,difluprednate. Int. J. Pharm, 301: 121-128.
144. Yamaguchi, T, K. Nishizaki, S. Itai, H. Hayashi and H. Ohashima, 1995. Physicochemicalcharacterization of parenteral lipid emulsion: Influence of cosurfactants on flocculation andcoalescence. Pharm. Res, 12: 1273-1278.
145. Yoo, H.S, S.M. Kwon, Y.J. Kima, H. Chung, I.C. Kwon, J. Kim and S.Y. Jeong, 2004. Cationiclipid emulsions containing heavy oils for the transfection of adherent cells. J. ControlledRelease, 98: 179-188.
146. Zapatero, D.C, X. Wittebole, V. Huberlant, M. Morunglav and P. Hantson, 2011. Lipid emulsion as rescue therapy in lamotrigine overdose. J. Emergency Med, 7: 1-4.